FIT screening

Colorectal cancer (CRC) is one of the most frequently diagnosed cancers. The good news is that CRC incidence and mortality can be reduced significantly if detected early enough.

Faecal immunochemical tests (FIT) are non-invasive and can detect blood in stool invisible to the naked eye. Due to its simplicity, FIT is currently considered the best non-invasive test for CRC screening.

Invest a little time in your own health by taking the FIT to prevent or detect colon cancer early on.
For further information, please visit our ‘FIT for screening’ website www.fitscreening.eu/patients

 

 

Please select your country. This will keep you up to date with your country-specific information.

OSNA in colorectal cancer

  • Precise lymph node analysis providing accurate staging
  • CE-marked for breast, colon and gastric cancer
  • Reliable diagnostic information for therapy decisions
  • Multi-cancer application allowing highly efficient analysis runs

The best therapy decision relies on accurate staging

Lymph node status is the most important prognostic factor and staging parameter in managing CRC. The current method to analyse lymph nodes is postoperative histopathology with one-section H&E: The lymph node is only analysed on one level, leaving a large amount of tissue not analysed. As a result, metastases may remain undetected, leading to false-negative results and a higher risk of disease recurrence.

By analysing the entire lymph node, OSNA delivers the confidence that you do not overlook any metastases. You can deliver accurate staging of the patients and a more reliable basis for your therapy decisions.

Lymph node analysis of pN0 patients with OSNA yielded an upstaging rate of up to 25% compared with the standard histological method1, studies have shown this allows adjusting the affected patients' management.

OSNA – Superior diagnostic information

  • Molecular determination of the tumour burden adds valuable clinical information
  • Quickly available results reduce waiting time for therapy decisions
  • Confidence not to overlook metastases by analysing the entire lymph node

Oncology

OSNA for CRC in clinical studies

OSNA for CRC in clinical studies

Recently, the OSNA result has shown to provide prognostic value in early-stage CRC patients (2). The OSNA-positive cases had a much lower three-year disease-free survival (DFS) rate than the negative ones. Among various clinical and pathological parameters, only the OSNA status was a significant prognostic factor, which can help select early-stage patients at risk of recurrence (2).

OSNA provides information about the lymph nodes’ (LN) positivity or negativity and allows obtaining the total tumour load (TTL), which is the sum of all CK19 mRNA copies present in all the positive LN of a given patient.

TTL correlates better with high-risk factors than pN stage and increases with the number of histologically positive LN (1,550 copies in pN0 patients, 24,050 in pN1 patients and 90,600 in pN2), as several authors showed (3). TTL represents a continuous value of the amount of tumour burden present in the LN, which may be more accurate than the pure number of positive LN.

Augment your expertise with advanced lymph node staging in colorectal cancer

Augment your expertise with advanced lymph node staging in colorectal cancer

Watch webinar with Pathologist Dr Miriam Cuatrecasas here

References

References

(1) Croner RS, Geppert C-I, Bader FG et al. (2014): Molecular staging of lymph node-negative colon carcinomas by one-step nucleic acid amplification (OSNA) results in upstaging of a quarter of patients in a prospective, European, multicentre study. Br. J. Cancer 110: 2544-2550.

(2) Matsuura N et al. (2017): Clinical impact of molecular positive lymph node status in colorectal cancer. Ann. of Oncol. 28 (suppl. 5): v158 – v208.

(3) Yamamoto H, Tomita N, Inomata M et al. (2015): OSNA-Assisted Molecular Staging in Colorectal Cancer: A Prospective Multicenter Trial in Japan. Ann. Surg. Oncol. 1-6.

Publications

Publications

Please see our publication list

Contact

Sysmex Europe GmbH

+49 (40) 527 26 0
+49 (40) 527 26 100
info@sysmex-europe.com
Bornbarch 1
22848 Norderstedt
Germany

Create Pdf

Learn how intraoperative sentinel lymph node analysis benefits cancer patients

Watch Penny’s story

Walk-Away FIT solutions for high throughput

Watch video

A step forward in colorectal cancer monitoring

Watch Carmen’s story
Enjoy our Media Centre
All
  • All
  • Documents
  • Podcast
  • Images
  • Videos
See our collection
Company movie